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Summary: In patients with cystic fibrosis plasma concentrations of Zn and Mg were unchanged, plasma Ca
concentrations were somewhat decreased, but plasma Fe concentrations were drastically reduced; the ratio
Cu/Fe in plasma was increased. The Mg and Zn contents of erythrocytes from patients were unchanged.
Therefore, the Mg and Zn content of erythrocytes cannot serve for the detection of patients with cystic
fibrosis and their heterozygotes, as has been suggested. Cl~-dependent Mg2+ efflux from Mg2"l"-loaded
erythrocytes was not affected in cystic fibrosis. Na+-dependent Mg24" efflux was increased only in erythrocytes
from patients with the most severe clinical symptoms.
Introduction
It has recently been reported that erythrocytes from
children with cystic fibrosis had significantly lower
median concentrations of Na, Mg and Zn, and a
higher median concentration of Ca than those of
healthy control children and the parents of the cystic
fibrosis children (1). Based on these results it was
suggested that an analysis of these elements can dis-
tinguish cystic fibrosis heterozygotes from healthy
controls and that the changed "erythrocyte concen-
trations of these elements reflect a primary defect of
the cystic fibrosis disease and very likely an impair-
ment of Cl~ transport function related to the DF508
mutation in the cystic fibrosis gene" (1).
In preceding experiments we have characterized Mg2+
efflux from erythrocytes. Mg2+ efflux from erythro-
cytes comprises amiloride-sensitive Na+/Mg2+ anti-
port and Na+-independent Mg2+ efflux which is com-
bined with Cl~ efflux for charge compensation. The
latter can be inhibited by high extracellular Cl~ con-
centration and by 4-acetamido-4/-isothiocyanatostil-
bene-2,2/-disulphonic acid (2, 3). As an additional
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proof of the reduced erythrocyte Mg content, and in
view of the fact that a part of Mg2+ efflux depends
on a functioning Cl~ transport, which might be dis-
turbed in cystic fibrosis, we measured the components




Heparinized blood was taken from 15 patients with cystic
fibrosis (6 males, 9 females, age range 5—22 years; mean 16).
The patients were treated according to their various clinical
symptoms. Additionally, they received 3 dragees/day of a mul-
tivitamin/mineral preparation (Eunova®). In addition to other
components, each dragee contained 7.3 mg Fe2+. Furthermore,
the patients received 40 mg Zn orotate and 100 mg vitamin E
per day.
For controls, heparinized blood was taken from 4 healthy
controls (age 18-38) and 4 patients (age 3-25) not suffering
from cystic fibrosis (atopic dermatitis, neuroses).
Blood was centrifuged at 1000 g for 10 min. The plasma and
buffy coat were aspirated. Plasma was taken for the measure-
ment of Mg, Ca, Zn, Fe and Cu by atomic absorption spectro-
photometry (AAS, Philips, SP 9). The erythrocytes were washed
twice with 150 mmol/1 KC1, then haemolysed by adding 750 μΐ
H2O. An aliquot (50 μΐ) of the haemolysate was taken for
determination of haemoglobin by the cyanomethaemoglobin
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method. The remainder was deproteinized by addition of 50 μΐ
750 g/l trichloroacetic acid, centrifuged, and the supernatant
taken for measurement of erythrocyte Mg and Zn by AAS after
dilution with 100 g/1 trichloroacetic acid/1.75 g/1 LaCl3.
The major part of the erythrocytes was taken for the measure-
ment of Mg2"1" efflux, as already described (4). The cells were
loaded with Mg2* by incubating a cell suspension (cell volume
fraction 0.1) for 30 min at 37 °C in KC1 medium (in mmol/1:
140 KC1, 12 MgCl2, 50 sucrose, 5 glucose, 30 Hepes/Tris, pH
7.4) with the addition of 6 μιηοΐ/ΐ of the cation ionophore
A23187 dissolved in dimethyl sulphoxide. For removal of the
ionophore, the cells were incubated four times in KC1 medium
plus 10 g/1 bovine serum albumin for 10 min at 37 °C. The KC1
medium was removed by washing the cells twice with cold
(4 °C) sucrose medium (in mmol/1: 350 sucrose, 5 glucose, 30
Hepes/Tris, pH 7.4).
Mg2* efflux was measured by reincubating a cell suspension
(cell volume fraction 0.1) at 37 °C in Mg2+-free NaCl medium
(substitution of KC1 in KC1 medium by 140 mmol/1 NaCl),
Mg^-free sucrose medium with or without 30 μηιοΙ/1 of the
anion exchange inhibitor 4-acetamido-4'-isothiocyanatostil-
bene-2,2/-disulphonic acid (Sigma), or Mg2+-free choline Cl
medium (substitution of KC1 in KC1 medium by 140 mmol/1
choline Cl).
At the beginning of reincubation and after 30 min, 0.5 ml
aliquots of the cell suspensions were centrifuged for l min at
10 000 g. Aliquots (100 μΐ) of supernatants were diluted with
1 ml 100 g/1 trichloroacetic acid/1.75 g/1 LaCl3, and Mg2+ was
measured by AAS. Mg2* efflux was calculated from the increase
of Mg2"1" in the reincubation media. Mg2+ efflux was expressed
in relation to cell volume. Cell concentration was determined
by the haematocrit, and by measuring the haemoglobin released
by cell lysis.
Results and Discussion
Mineral content of plasma and erythrocytes
Plasma concentrations of Mg and Zn were not sig-
nificantly different in controls and patients with cystic
fibrosis. The Ca concentration in the plasma of cystic
fibrosis patients was 0.1 mmol/1 lower than in the
controls, but it was within the normal range. Some
cystic fibrosis patients with expressed maldigestion-
malabsorption showed a reduction in plasma Mg.
These patients exhibited clinical symptoms of hypo-
magnesaemia, e. g. paraesthesias.
Plasma Fe concentration was reduced in cystic fibro-
sis, although the patients had received Fe supplemen-
tation for several weeks. Plasma Cu was increased.
The increase in Cu was not significant. However, there
was a significant difference in the Cu/Fe ratio between
controls and cystic fibrosis patients (tab. 1). This
effect may represent an acute phase reaction due to
infections.
Mg and Zn concentrations in erythrocytes were not
significantly different in controls and cystic fibrosis
patients (tab. 2); this finding contradicts published
data (1).
Tab. 2. Mg and Zn content of erythrocytes from patients with
cystic fibrosis and controls. Mean ± SEM. No statis-
tical significance by unpaired Student's t-test.











A possible explanation for this discrepancy may be a
better alimentary supply of Mg and Zn in the cystic
fibrosis patients in our study, which were supple-
mented with 6.3 mg Zn/day as Zn orotate. Since the
authors of the previous study (1) did not measure
serum Mg and serum Zn concentrations and since
maldigestion-malabsorption is common in cystic fi-
brosis, this assumption cannot be ruled out. Probably,
the decrease in erythrocyte Mg and Zn is only a
secondary complication of cystic fibrosis, as already
suggested for Zn in cystic fibrosis (5).
Another possible reason for the difference between
our findings and those of the previous study may be
the method used to determine Mg and Zn. As meas-
ured by particle-induced X-ray emission, Mg and Zn
in control erythrocytes amounted to 2.84 and 0.34
mmol/kg dry weight (1), whereas the Mg and Zn
contents of erythrocytes measured by atomic absorp-
tion spectrophotometry were 2.3 mmol/1 cells for Mg
(6, 7, 8, 9) and 0.15 mmol/1 cells ((10), tab. 2) or 0.2-
0.3 mmol/1 cells for Zn (7, 8). Measurement of eryth-
rocyte Ca was omitted in the present investigation,
because the published values for erythrocyte Ca show
wide variations.
The true erythrocyte Ca content is extremely low
(1 μιηοΐ/ΐ cells (6)) and is sensitive to various contam-
inations (6). The major part of erythrocyte Ca is
bound to the external site of the erythrocyte mem-
brane and the extent of its removal varies with the
washing procedure (6).
Tab. 1. Concentration of Mg, Ca, Zn, Fe and Cu in plasma of patients with cystic fibrosis and controls. Mean ± SEM. Statistical
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Mg2+ efflux
As an additional test for a potential decrease in eryth-
rocyte Mg in patients with cystic fibrosis, we measured
Mg2+ efflux from Mg2+-loaded erythrocytes. There
was an insignificant increase in Na+-dependent Mg2+
efflux, which operates via Na+/Mg2+ antiport (tab.
3). However, when the patients were grouped accord-
ing to their clinical symptoms (1 = mild,
2 = medium, 3 = severe clinical symptoms (accord-
ing to Shwachman & Kulczyzki (11)), erythrocytes
with high Na^/Mg2* antiport were derived from pa-
tients with severe clinical symptoms of cystic fibrosis
(fig. 1, tab. 4). Probably, there is a structural alteration
in the erythrocyte membrane of these patients, but
the mechanism is still unclear. Since most of these
patients inhaled amiloride, which inhibits Na+/Mg2+
Tab. 3. Mg2+ efflux from erythrocytes from patients with cystic
fibrosis and controls in NaCl, choline chloride and
sucrose medium. 4-Acetamido-4'-isothiocyanatostil-
bene-2,2'-disulphonic acid (SITS): 30 μιηοΐ/ΐ.
Mg2"1" efflux values in mmol/30 min χ 1 cells. Mean





Controls 0.34 + 0.03 0.10 + 0.01




0.88 + 0.05 0.18 + 0.02
0.92 + 0.05 0.16 + 0.01
Na+/Mg2+ antiport (Mg2+ efflux in NaCl minus Mg2+ efflux
in choline chloride medium) is 0.24 + 0.04 mmol/30 min χ Ι










Fig. 1. Na+/Mg2+ antiport in erythrocytes from controls and
patients with cystic fibrosis, grouped according to the
severity of disease.
Values represent the difference of Mg2"1" efflux in NaCl
medium minus Mg2+ efflux in choline chloride medium.
antiport (7), it may be speculated whether the in-
creased Na+/Mg2+ antiport in these patients is a
compensatory effect. However, the patient with the
highest rate of Na+/Mg2+ antiport did not tolerate
amiloride inhalation. Na+-independent Mg2+ efflux,
which operates in combination with Cl~ efflux, and
which is inhibited by 4-acetamido-4'-isothiocyanato-
stilbene-2,2'-disulphonic acid and Cl~, was not
changed in cystic fibrosis (tab. 3).
Tab. 4. Age (years), body weight (kg), sex, severity of disease (score 1 — 3 = mild, medium or severe clinical symptoms); erythrocyte
Mg- and Zn-concentration (E-Mg and E-Zn, mmol/1 cells); plasma Mg-concentration (P-Mg, mmol/1); plasma Zn-
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The biochemical defect in cystic fibrosis is a mutation
of the cAMP-dependent Cl~ channel in airway and
intestinal epithelia (12). Cl~-transport in erythrocytes
is performed by an anion exchange protein (band 3,
capnophorin) (13), which is different from the Cl
channel of secretory cells. This explains, why the Na+-
independent (Cl~-dependent) Mg24" efflux is un-
changed in erythrocytes from cystic fibrosis patients.
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